Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism

Campello, Elena; Spiezia, Luca; Radu, Claudia; Bulato, Cristiana; Castelli, Monica; Gavasso, Sabrina; Simioni, Paolo

doi:10.1016/j.thromres.2011.01.002

Cited by 125 publications

(127 citation statements)

References 29 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…A previous study by Duchemin et al (26) documented increased thrombin generation in MPN patients. This result is compatible with previous observations in patients with other cancers (27). Splenomegaly, resulting from extramedullary haematopoiesis, is present in almost all PMF patients and a subset of ET and PV patients at diagnosis.…”

Section: Discussionsupporting

confidence: 92%

Clinical significance of circulating microparticles in Ph− myeloproliferative neoplasms

Zhou

Zhao

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Clinical significance of circulating microparticles in Ph− myeloproliferative neoplasms

Zhou

Zhao

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

“…Moreover, therapy with low molecular weight heparin seems to reduce MPs levels more effectively than oral anticoagulant [54,55]. The role of MPs as (ii) prognostic biomarkers for VTE has also been assessed, though mostly in cancer subpopulations [43,46,[56][57][58][59][60][61]. The findings suggest that TF-bearing MPs detected both by flowcytometry and by the functional MP-TF activity yielded promising results as potential prognostic biomarkers for VTE, especially in pancreatic and brain cancer.…”

Section: Mps and Venous Thrombosismentioning

confidence: 99%

Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: a role for circulating microparticles?

Campello

Radu

Spiezia

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

Self Cite

View full text Add to dashboard Cite

Over the past decades, there have been great advances in the understanding of the pathogenesis of venous thromboembolism (VTE) in patients with inherited and acquired thrombophilia [mainly antiphospholipid antibody syndrome (APS)]. However, a number of questions remain unanswered. Prognostic markers capable of estimating the individual VTE risk would be of great use. Microparticles (MPs) are sub-micron membrane vesicles constitutively released from the surface of cells after cellular activation and apoptosis. The effects of MPs on thrombogenesis include the exposure of phopshatidylserine and the expression of tissue factor and MPs have been described in clinical studies as possible diagnostic and prognostic biomarkers for VTE. This review will provide a novel perspective on the current knowledge and research trends on the possible role of MPs in hereditary thrombophilia and APS. Basically, the published data show that circulating MPs may contribute to the development of VTE in thrombophilic carriers, both in mild and severe states. Moreover, the presence of endothelial-MPs and plateletMPs has been described in antiphospholipid syndrome and seems to be directly linked to antiphospholipid antibodies and not to other underlying autoimmune disorders or the thrombotic event itself. In conclusion, circulating MPs may constitute an epiphenomenon of thrombophilia itself and could be up-regulated in acute particular conditions, promoting a global prothrombotic state up to the threshold of the clinical relevant thrombotic event.

show abstract

“…Rather than one unifying mechanism, the etiology is likely multifactorial with [19,20] Several studies have focused on the role of Tissue Factor (TF) in the pathophysiology of cancer related thrombosis. Tissue factor (TF) is the physiologic initiator of coagulation and is commonly expressed in a variety of malignancies.…”

Section: Pathogenesis Of Vte In Cancer: Evidences For Colorectal Cancermentioning

confidence: 99%

Venous Thromboembolism and Colorectal Cancer: A Review

Ding¹

2017

WJPR

View full text Add to dashboard Cite

Venous thromboembolism is a common complication of malignancies and epidemiological studies suggested that colorectal cancer belong to the group of malignancies with the highest incidence rates of VTE.Risk factor for VTE in colorectal cancer patients are advanced disease, colorectal surgery and chemotherapy including anti-angiogenic therapy.Other risk factors are pretreatment platelet counts and increased release of TF-positive micro-particles. Elevated D-dimer level do not necessarily indicate an increased risk of VTE but have been shown to be predictive for a worse clinical outcome in colorectal cancer patients.Mechanisms responsible for the increase in venous thrombosis in patients with colorectal cancer are not understood. Currently no biomarker is recognized as a predictor for VTE in colorectal cancer.Although several clinical trials have reported the efficacy of antithrombotic prophylaxis in patients with colorectal cancer who are receiving chemotherapy, further trials are needed to assess the clinical benefit since these patients are at an increased risk of developing a thromboembolism.

show abstract

Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism

Cited by 125 publications

References 29 publications

Clinical significance of circulating microparticles in Ph− myeloproliferative neoplasms

Clinical significance of circulating microparticles in Ph− myeloproliferative neoplasms

Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: a role for circulating microparticles?

Venous Thromboembolism and Colorectal Cancer: A Review

Contact Info

Product

Resources

About